NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Tags: melanoma


It’s way too soon to know if melanoma blood test will save ‘thousands of lives’


HealthDay cautiously reports results of Opdivo melanoma study


It’s misleading to call results from phase 1 trials with 6 and 13 patients a ‘cancer breakthrough’


‘Game-changer, Holy Grail, groundbreaking’ used in Philly Inquirer story on phase 1 trial


Reuters Health briefly but aptly reports survey findings of partner-assisted skin exams for melanoma survivors


Except for presidential anecdote, NBC story on new melanoma drug was well-balanced


Coverage of virus-based cancer treatment skimps on cautions and key outcomes


Keytruda and colon cancer: coverage of benefits not balanced with harms and cost info


Survival statistic unbalances coverage of virus-based melanoma therapy

1 5/18/2015

Rosy CBS report on vitamin study lacks meaningful description of skin cancer impact